Clinical Trial

Feasibility of a Smartphone Application for Asthma Self-management

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 2, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary goal of this project is to determine the feasibility, acceptability, and adherence of a smartphone application for improving asthma self-management in a pilot randomized controlled trial (RCT). The app is specifically designed to appeal to adolescents. Adolescents with persistent asthma will be randomized to receive: 1) standard-of-care or 2) the self-management app in addition to standard-of-care. Feasibility will be assessed by the ability to recruit and retain subjects, technical barriers to implementation, and the appropriateness of the intervention among adolescents and providers. The acceptability of the intervention will be determined by appraising perceived usefulness, entertainment, and ease of use of the app. Adherence to usage of the app over a 6-month period will be assessed by examining the frequency of app usage and the features that were used, and the extent of data regarding self-management that was entered. A secondary objective is to obtain preliminary estimates of effectiveness of the app on clinical outcomes (ACT score, spirometry, CHSA-C, exacerbations, and medication adherence) relative to standard-of-care. It is hypothesized that the app will result in a high level of adherence and will be a feasible and acceptable intervention to improve self-management among adolescents with persistent asthma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-10-05; most recent amendment 2024-09-30.
Status change: Not Yet Recruiting → Recruiting 2023-06-21
Trial Details
NCT Number NCT05572177
Lead Sponsor University of South Florida
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Asthma Chronic
Enrollment 50 participants
Start Date 2023-06-26
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-02